Physician profile
Jose E Ramos
NPI 1841210077
$3,698.23
in general payments reported to CMS, 2019-2025
14 companies · $98.93 in 2025
The $98.93 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $449 · 2021: $880 · 2022: $639 · 2023: $662 · 2024: $453 · 2025: $98.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,063.45 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $526.44 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.99 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $404.05 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $250.43 | 2019-2024 | Farxiga, Lokelma |
| Novo Nordisk INC | $241.54 | 2021-2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $220.28 | 2019-2024 | Watchman Flx |
| Pbg Puerto Rico LLC | $218.61 | 2020-2024 | |
| Amgen INC. | $158.13 | 2019-2023 | Repatha |
| Chiesi USA, INC. | $91.25 | 2021 | |
| Merck Sharp & Dohme LLC | $22.30 | 2024 | Verquvo, Januvia, Winrevair |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.18 | 2022 | |
| Gilead Sciences, INC. | $15.25 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.